Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase

Journal of Virology

Volumn 71, Issue 6, 1997, Pages 4752-4760

  Panousis, Constantinos G ^a   Rowe, David T ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; IMMUNOGLOBULIN RECEPTOR; MALTOSE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; POLYCLONAL ANTIBODY; PROTEIN SERINE KINASE; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS LATENCY;

EID: 0030962177     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.6.4752-4760.1997     Document Type: Article

References (67)

1. Alber, G., K. Kim, P. Weiser, C. Riesterer, R. Carsetti, and M. Reth. 1993. Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukemia virus. Curr. Biol. 3:333-339.
2. Alfieri, C., M. Berkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608.
3. Allday, M., D. Crawford, and B. Griffin. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70:1755-1764.
4. Alvarez, E., I. Northwood, F. Gonzalez, D. Latour, A. Seth, C. Abate, T. Curran, and R. Davis. 1991. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. J. Biol. Chem. 266:15277-15285.
5. Beaufils, P., D. Choquet, R. Mamoun, and B. Malishen. 1993. The (YXXL/ I)2 signalling motif found in the cytoplasmic segments of the bovine leukemia virus envelope protein and the Epstein-Barr virus latent membrane prolein 2A can elicit early and late lymphocyte activation. EMBO J. 12:5105-5112.
6. Brunswick, M., C. June, and J. Modd. 1994. B lymphocyte immunoglobulin receptor desensitization is downstream of tyrosine activation. Cell. Immunol. 156:240-244.
7. Burkhardt, A., J. Bolen, E. Kieff, and R. Longnecker. 1992. An Epstein-Barr virus transformation-associated membrane protein interacts with Src family tyrosine kinases. J. Virol. 66:5161-5167.
8. Busson, P., R. Edwards, T. Tursz, and N. Raab-Traub. 1995. Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J. Gen. Virol. 76:139-145.
9. Cambier, J., C. Pleiman, and M. R. Clark. 1994. Signal transduction by the B cell antigen receptor and its coreceptors. Annu. Rev. Immunol. 12:457-486.
10. Chan, M., L. Stein, H. Dosch, and N. Sigal. 1986. Heterogeneity of EBV-transformable human B lymphocyte populations. J. Immunol. 136:106-112.
11. Cohen, J., and E. Kieff. 1991. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J. Virol. 65:5880-5885.
12. Cordier-Busset, M., M. Billand, A. Calender, and G. Lenoir. 1993. Epstein-Barr virus (EBV) nuclear antigen 2 induced upregulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int. J. Cancer 53:153-160.
13. David, M., E. Petricoin III, C. Benjamin, R. Pine, M. Weber, and A. Larner. 1995. Requirement for MAP kinase (ERK2) activity in interferon α-and interferon β-stimulated gene expression through STAT proteins. Science 269:1721-1723.
14. Davis, J. D. 1993. The Mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
15. DeFranco, A. 1993. Structure and function of the B cell antigen receptor. Annu. Rev. Biol. 9:377-410.
16. Franken, M., A. Bethany, A. Ali, and F. Wang. 1995. 5′ coding and regulatory region sequence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J. Virol. 69:8011-8019.
17. Gerber, P., and J. Monroe. 1968. Studies on leukocytes growing in continuous culture derived from normal human donors. J. Natl. Cancer Inst. 40: 855-866.
18. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus (EBV) B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J. Gen. Virol. 71:1481-1495.
19. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (London) 340:393-397.
20. Henderson, E., G. Miller, J. Robinson, and L. Heston. 1977. Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology 76:152-163.
21. Henderson, S., M. Rowe, and C. Gregory. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 65:1071-1115.
22. Jin, X., and S. Speck. 1992. Identification of critical cis elements involving in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J. Virol. 66: 2846-2852.
23. Kempes, B., D. Pich, R. Zeidler, B. Sugden, and W. Hammerschmidt. 1995. Immortalization of human B lymphocytes by a plasmid containing 71 kbp of Epstein-Barr virus DNA. J. Virol. 69:231-238.
24. Khanna, R., S. Burrows, and D. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
25. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, et al. (ed.), Fields virology. Raven Press, New York, N.Y.
26. Kim, O., and J. Yates. 1993. Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture. J. Virol. 67:7634-7640.
27. Klein, G. 1994. Epstein-Barr virus in normal and neoplastic B cells. Cell 77:791-793.
28. Knutson, J. C. 1990. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64: 2530-2536.
29. Laux, C., M. Perricaudet, and P. Farrell. 1988. A spliced Epstein-Barr virus eene expressed in immortalized lymphocytes is created by circulation of the linear genome. EMBO J. 7:769-775.
30. Lewin, N., P. Aman, M. Masucci, E. Klein, B. Klein, H. Oberg, W. Strander, G. Henle, and G. Henle. 1987. Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release ol transforming virus and spontaneous outgrowth. Intl. J. Cancer 39:472-476.
31. protork. Neuron 9:1053-1065.
32. Longnecker, R., B. Druker, T. Roberts, and E. Kieff. 1991. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J. Virol. 65:3681-3692.
33. Longnecker, R., C. Miller, X. Miao, A. Marchini, and E. Kieff. 1992. The only domain that distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; EMP2A is therefore nonessential. J. Virol. 66:6461-6469.
34. Longnecker, R., C. Miller, X. Miao, B. Tomkinson, and E. Kieff. 1993. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein (LMP2A) are dispensable for lymphocyte infection and growth transformation in vitro. J. Virol. 67:2006-2013.
35. Longnecker, R., C. Miller, B. Tomkinson, X. Miao, and E. Kieff. 1993. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J. Virol. 67:5068-5074.
36. Marshall, D., and C. Sample. 1995. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J. Virol. 69:3624-3630.
37. Masucci, M. G. 1993. Viral immunopathology of human tumors. Curr. Opin. Immunol. 5:693-700.
38. Miller, C., R. Longnecker, and E. Kieff. 1993. Epstein-Barr virus latent membrane prowtein 2A blocks calcium mobilization in B lymphocytes. J. Virol. 67:3087-3094.
39. Miller, C., J. Lee, E. Kieff, A. Burkhardt, J. Bolen, and R. Longnecker. 1994. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in slg-mediated signal transduction. Infect. Agents Dis. 3:128-136.
40. Miller, C., J. Lee, E. Kieff, and R. Longnecker. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl. Acad. Sci. USA 91:772-776.
41. Miller, C., A. Burkhardt, J. Lee, B. Stealy, R. Longnecker, J. Bolen, and E. Kieff. 1995. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155-166.
42. Morrison, P., A. Saltier, and M. Rosner. 1996. Role of mitogen-activated protein kinase kinase in regulation of the epidermal growth factor receptor by protein kinase C. J. Biol Chem. 271:12891-12896.
43. Mosialos, R., M. Birkenbach, R. Yalamanchili, T. Van Arsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-400.
44. Moss, D., C. Bishop, and J. Ryan. 1985. T lymphocytes in infectious mononucleosis. I. T cell death in vitro. Clin. Exp. Immunol. 60:61-69.
45. Northwood, I. C., F. Gonzalez, M. Wartmann, D. Raden, and R. Davis. 1991. Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. J. Biol. Chem. 266:15266-15276.
46. Preiksaitis, J., F. Diaz-Mitoma, F. Mirzayans, F. Roberts, and D. Tyrrell. 1992. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorders. J. Infect. Dis. 166:986-994.
47. Qu, L., and D. Rowe. 1992. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66:3715-3724.
48. Rawlins, D., G. Milman, S. Hayward, and G. Hayward. 1985. Sequence specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42:859-868.
49. Rickinson, A. B. 1986. Cellular immunological responses to infection, p. 75-125. In M. A. Epstein and B. G. Anchong (ed.), The Epstein-Barr virus: recent advances. William Heinemann, London, England.
50. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, et al. (ed.), Fields virology. Raven Press, New York, N.Y.
51. Sample, J., E. Henson, and C. Sample. 1992. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66: 4654-4661.
52. Sample, J., D. Liebowitz, and E. Kieff. 1989. Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J. Virol. 63:2743-2753.
53. Sarkar, G., and S. Sommer. 1990. The "Megaprimer" method of site directed mutagenesis. BioTechniques 8:404-407.
54. Schuh, S., E. Newberry, M. Dalton, and L. Pike. 1994. Mutation of proline 1003 to glycine in the epidermal growth factor (EGF) receptor enhances responsiveness to EGF. Mol. Cell. Biol. 5:739-746.
55. Sinclair, A., and P. Farrel. 1995. Host cell requirement for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J. Virol. 69:5461-5468.
56. Songyang, Z., S. Shoelson, M. Chauhduri, G. Giah, T. Pawson, H. Hanafusa, B. Schaffhausen, and L. Cantley. 1993. SH2 domains recognize specific phosphopeptide sequences. Cell 72:767-778.
57. Sugden, B., and W. Mark. 1977. Clonal transformation of adult human leukocytes by Epstein-Barr virus. J. Virol. 23:503-508.
58. Takishima, K., I. Griswold-Prenner, T. Ingrebitsen, and M. R. Rosner. Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. Proc. Natl. Acad. Sci. USA 88: 2520-2524.
59. Thorley-Dawson, D. A. 1988. Immunological responses to Epstein-Barr virus infection and the pathogenesis of EBV-induced diseases. Biochim. Biophy. Acta 948:263-286.
60. Thorley-Dawson, D. A., and K. Mann. 1985. Early events in EBV infection provide a model for B cell activation. J. Exp. Med. 162:45-57.
61. Tierney R., N. Stevens, L. Young, and A. Rickinson. 1994. Epstein-Barr virus latency in mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
62. Tomkinson, B., and E. Kieff. 1992. Use of second site homologous recomhination to demonstrate that Epstein-Barr virus nuclear protein EBNA-3B is not important for B-lymphocyte infection or growth transformation in vitro. J Virol. 66:2893-2903.
63. Volonte, C., J. Angelastro, and L. Greene. 1993. Association of protein kinases erk1 and erk2 with p75 nerve growth factor receptors. J. Biol. Chem. 268:21410-21415.
64. k to DNA. J. Virol. 70:5909-5915.
65. Wang, F., C. Gregory, J. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent infection membrane and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP cooperatively induce CD23. J. Virol. 64: 2309-2318.
66. Yao, Q., and A. Rinckinson. 1991. Spontaneous outgrowth of Epstein-Barr virus positive B cells lines from circulating human B cells of different buoyant densities. Int. J. Cancer 48:253-257.
67. Zimber-Strobl, U., K. Suentezenich, G. Laux, D. Eick, M. Cordier, A. Calender, M. Billaud, G. Lenoir, and G. Bornkamm. 1991. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J. Virol. 65:415-423.